Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Launched by CHILDREN'S MERCY HOSPITAL KANSAS CITY · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called trihexyphenidyl works in children with dystonic cerebral palsy, a condition that causes muscle stiffness and movement difficulties. The researchers want to find out how the body breaks down this medicine and how genetics might affect its effectiveness and side effects in young patients. By understanding these factors, they hope to improve treatments for children with this condition in the future.

To participate in the study, children must be between 5 and 17 years old and have a diagnosis of cerebral palsy with dystonia that affects their daily life. Parents or guardians must be willing to provide permission for their child to join the study. Participants will not be able to take trihexyphenidyl during the trial, and those who will turn 18 within the study period are not eligible. The study is currently looking for volunteers, and it aims to gather valuable information that could help design better clinical trials for treating dystonic cerebral palsy in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages 5-17 years of age
• • Diagnosis of cerebral palsy and dystonia causing interference
• • Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
• • Parent/legal guardian is willing and able to provide informed permission/assent for the study
• Exclusion Criteria:
• • Previously or currently taking trihexyphenidyl
• • Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
• • A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements